

Perspectives of Authors in General Medical and Nursing Journals towards the PRISMA

1. Country of affliation (i.e. w	here you are based at now):	Afghanistan	‡
2. What is your specialty (i.e.	area of specialty)?		
Anaesthesia	Orthopaedic		
Anatomy	Otolaryngology		
Biochemistry	 Paediatrics 		
Dentistry	Pathology		
3. Age group (years)			
21-30			
31-40			
41-50			
51-60			
61 or above			
4. Gender			
Female			
Male			
5. Your years of experience in o	conducting academic research	(years):	
Text			
6. Do you know what is system	natic review?		
Yes			
○ No			
7. Have you published any syst	tematic review?		
Yes			
○ No			
8. Are you aware of the Prefer	red Reporting Items for Syste	matic Reviews and Meta-Analyses (Pi	RISMA) guideline?
Yes			
○ No			

9. Do you	follow the PF	RISMA guidelir	ne whencondu	cting and repo	orting your sys	tematic review	<i>i</i> ?			
O Yes										
O No (n	ot required by	journals or orga	anisations)							
No (o	ther reasons)									
O Not a	pplicable (did r	not conduct any	y systematic re	view)						
	pplicable (othe		, -,	,						
	ppilodolo (otilo									
10. Rate t	the importanc	e to follow the	PRISMA guid	eline in condu	cting and repo	rting of syster	natic reviews i	in journals:		
1: Not im	nportant,, 10	: Very importan	t			ı	ı		ı	
O N/A	1	2	3	4	5	6	7	8	9	10
107		-	Ü	•	Ü	Ü		Ü		
In the t	following	we would	l like vou	to rate the	importan	e of each	item in th	e PRISMA	quideline	(1:
	_		-		-			C I KIOWA	garacinic	(
Not im	portant, .	, 10: very	y importar	nt) and the	reason of	your ratir	ig if any.			
11a. Item	related to the	Title								
Item 1: Ir	dentify the ren	ort as a system	atic review me	ta-analysis, or b	ooth					
nem i. k	uchary are repo	ort as a system	allo review, me	ta-analysis, or b	Jouri.	ı	ı	1	ı	
N/A	1	2	3	4	5	6	7	8	9	10
11b . Rea	son for your r	ating (optiona	ıl):							
Text										
12a. Item	related to the	Abstract								
		-	_	pplicable: backo ; results; limitati	-			-		ation
number.	ions, study app	naisai and sym	uiesis illeulous	, results, illilitati	ioris, coriciasioi	is and implicati	ons of key into	ngs, systematic	review registre	ition
0	1	ı	ı	ı	1	1	ı	1	1	
N/A	1	2	3	4	5	6	7	8	9	10
12b. Reas	on for your ra	ating (optional):							
Text										
TOAL										
13a. Item	s related to	the Introduc	tion							
Item 3: D	escribe the rat	tionale for the r	eview in the co	ntext of what is	already known.					
U.A	1	-	3	1	-	6	7	8	9	10
N/A	1	2		4	5	-			-	10
design (F		icit statement o	r questions bei	ng addressed w	vith reference to	participants, ir	iterventions, co	mparisons, out	comes, and stu	ay
Georgii (i	1000).	ı	ı	ı	1	ı	ı	ı	1	
N/A	1	2	3	4	5	6	7	8	9	10
		-	ŭ	1	·	·		•	v	10
13b. Reas	on for your ra	ating (optional):							
Text										

14a. Items related to the Methods

including re	egistration nu	mber.				,			on information	
<i>)</i> // A	1	2	3	4	5	6	7	8	9	10
-		aracteristics (e.		gth of follow-up) and report cha	aracteristics (e	.g., years consid	dered, language	, publication sta	atus)
						ı	ı			
/A	1	2	3	4	5	6	7	8	9	10
	scribe all infor ast searched.	mation sources	s (e.g., databas	ses with dates o	of coverage, cor	itact with study	authors to ider	itify additional st	udies) in the se	earch
) /A	1	2	3	4	5	6	7	8	9	10
	sent full elect		•	ast one databas	-	v limits used. s	uch that it could	be repeated	3	1
)	1				,g	,			ı	
/A	1	2	3	4	5	6	7	8	9	10
tem 9: Sta	te the proces	s for selecting s	studies (i.e., sc	reening, eligibil	ity, included in s	systematic revi	ew, and, if appli	cable, included i	n the meta-ana	alysis).
) /A	1	2	3	4	5	6	7	8	q	10
	escribe metho		ction from repo	orts (e.a., pilotec	•	ndently, in dup	licate) and any	orocesses for ob	otaining and	
	data from inv			, priories	, , , , , ,				, and	
/ A	1	2	3	4	5	6	7	8	9	10
Item 11: Lis	st and define	all variables for	which data we	ere sought (e.g.	, PICOS, fundin	g sources) and	d any assumptio	ns and simplific	ations made.	
/A	1	2	3	4	5	6	7	8	9	10
Item 12: D	escribe meth	ods used for as	ssessing risk o	f bias of individu	ual studies (incl	uding specifica	ation of whether	this was done a	at the study or	
outcome l	evel), and ho	w this informati	on is to be use	d in any data sy	nthesis.					
Q		2	3		5	6	7	8		
N/A Item 13: S	tate the princ	inal summary r	ŭ	, risk ratio, diffe	•	·	,	0	9	
10.0	tate the phile	ipai sairiiriary i	neasures (e.g.	, risk rado, dilic	Terroe III III caris	,	ı	I	ı	
N/A	1	2	3	4	5	6	7	8	9	
Item 14: Danalysis.	escribe the n	nethods of hand	dling data and	combining resu	lts of studies, if	done, includin	g measures of o	consistency (e.g	., I ²) for each m	neta-
O	1	ı	I I	1	I I	1	I	I I	I I	
N/A	1	2	3	4	5	6	7	8	9	
Item 15: S	pecify any as	sessment of ris	sk of bias that	may affect the c	umulative evide	ence (e.g., pub	lication bias, se	lective reporting	within studies)).
Ų N/A	1	2	3	4	5	6	7	8	9	
	escribe meth					-		e, indicating whi	-	
0	ı	1		,	, , , , , , , , , , , , , , , , , , ,	,,	, ,	.,	1	
N/A	1	2	3	4	5	6	7	8	9	
4b. Reaso	on for your ra	ating (optional):							

15a. Items related to the Results

Text

Item 17:		of studies scre	ened, assesse	d for eligibility, a	and included in	the review, with	reasons for ex	clusions at eac	n stage, ideally	with a
							1	1	1	
N/A	1	2	3	4	5	6	7	8	9	10
Item 18:	For each study	y, present chara	acteristics for w	hich data were	extracted (e.g.,	study size, PIC	OS, follow-up	period) and pro	vide the citation	s.
0	1	1	1		1	1	1	1	1	
N/A	1	2	3	4	5	6	7	8	9	10
Item 19:	Present data d	on risk of bias o	of each study ar	nd, if available,	any outcome le	vel assessment	(see item 12).			
0						1				
N/A	1	2	3	4	5	6	7	8	9	10
			(benefits or har eally with a fore	ms), present, fo	or each study: (a	a) simple summ	nary data for ea	ch intervention	group (b) effect	1
0							1	1		
N/A	1	2	3	4	5	6	7	8	9	10
Item 21:	Present result	s of each meta-	-analysis done,	including confid	dence intervals	and measures	of consistency.			
0							1	1		
N/A	1	2	3	4	5	6	7	8	9	10
Item 22:	Present result	s of any assess	sment of risk of	bias across stu	dies (see Item	15).				
0					1		1	1		
N/A	1	2	3	4	5	6	7	8	9	10
Item 23:	Give results of	f additional ana	lyses, if done (e.g., sensitivity	or subgroup an	alyses, meta-re	gression [see It	em 16]).		
0							1	1		
N/A	1	2	3	4	5	6	7	8	9	10
15b. Reas	on for your r	ating (optiona	1):							

16a. Items related to the Discussion

